New Medications
Resource Center
Featured
01/31/2025
Kate Young
The FDA has approved suzetrigine 50 milligram oral tablets for moderate to severe acute pain in adults. The drug acts on the peripheral nervous system before pain signals can reach the brain, eliminating...
01/31/2025
12/18/2024
Miranda Manier, BA
In a phase 3 trial, inebilizumab, a monoclonal antibody targeting CD19+ B cells, reduced flare rates and improved treatment-free and glucocorticoid-free remission in patients with immunoglobulin G4-related...
12/18/2024
10/15/2024
Miranda Manier, BA
Two phase 3 randomized trials evaluated the efficacy of risankizumab in patients with moderately to severely active ulcerative colitis. The results show significantly higher remission rates with...
10/15/2024
Interactive Features
08/13/2016
Joshua is an 80-year-old man who had been stable on coumadin for 12 months, consistently demonstrating an INR of 2.2 to 3.1. Today, Joshua presented with an INR of 21.4, which results in immediate admission...
08/13/2016
Oral and Perioral Lesions
Oral and Perioral Lesions
03/03/2016
We previously met Zeke, a 19-year-old college student with a history of recurrent aphthous ulcers.
03/03/2016
11/22/2015
Researchers recently investigated inebilizumab as a potential treatment option for patients with immunoglobulin G4-related disease. Test your understanding of the findings!
11/22/2015
09/22/2014
We previously met Louis, a healthy 68-year-old male who currently takes no medications but has been reluctant to start statin use due to concerns that it may cause dementia. Today, you receive a call from...
09/22/2014
Clinical Insights
09/12/2020
In this 7-minute video, Dr Hudesman recaps his presentation on new and emerging therapeutic targets in IBD.
09/12/2020
Inflammatory Bowel Disease
Inflammatory Bowel Disease
07/25/2020
David Rubin, MD, review his talk at the virtual AIBD 2020 regional meeting July 25 on new and emerging therapeutics for inflammatory bowel disease.
07/25/2020
07/15/2020
He discusses his session on endocrine pathways and therapeutic options for patients with nonalcoholic fatty liver disease, which he presented at Harvard University’s 21st Annual Symposium on NAFLD.
07/15/2020
03/08/2015
In this article Michael J. Bloch, MD, writes about the potential use of a polypill for cardiovascular disease prevention and discusses how the results of recent research supports the potential use in the...
03/08/2015
